Oppenheimer Remains a Buy on Inovio Pharmaceuticals (INO)
Oppenheimer analyst Hartaj Singh reiterated a Buy rating on Inovio Pharmaceuticals on August 20 and set a price target of $13.00. The company’s shares closed yesterday at $1.91.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Singh is ranked #2710 out of 9923 analysts.
Inovio Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $5.45, representing a 185.34% upside. In a report released on August 13, Piper Sandler also maintained a Buy rating on the stock with a $5.00 price target.
INO market cap is currently $103.1M and has a P/E ratio of -0.71.
Read More on INO:
Disclaimer & DisclosureReport an Issue
- Inovio Pharmaceuticals: Hold Rating Amid Financial Challenges and Competitive Pressures
- Inovio Pharmaceuticals Reports Q2 2025 Financial Progress
- Inovio reports Q2 EPS (61c), consensus (62c)
- Options Volatility and Implied Earnings Moves Today, August 12, 2025
- Inovio announces peer-reviewed data from INO-3107 study
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.